Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Non-Current Liabilities (2018 - 2023)

China Pharma Holdings (CPHI) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $10.5 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Total Non-Current Liabilities changed N/A year-over-year to $10.5 million, compared with a TTM value of $10.5 million through Mar 2023, changed N/A, and an annual FY2022 reading of $11.1 million, down 24.71% over the prior year.
  • Total Non-Current Liabilities was $10.5 million for Q1 2023 at China Pharma Holdings, down from $11.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $14.7 million in Q4 2021 and bottomed at $9.6 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $11.0 million, with a median of $10.5 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities surged 42.28% in 2021, then dropped 24.71% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $10.6 million in 2019, then decreased by 2.18% to $10.4 million in 2020, then soared by 42.28% to $14.7 million in 2021, then decreased by 24.71% to $11.1 million in 2022, then dropped by 5.3% to $10.5 million in 2023.
  • Business Quant data shows Total Non-Current Liabilities for CPHI at $10.5 million in Q1 2023, $11.1 million in Q4 2022, and $14.7 million in Q4 2021.